DK0830141T3 - Forbedrede virusvacciner - Google Patents
Forbedrede virusvaccinerInfo
- Publication number
- DK0830141T3 DK0830141T3 DK96913234T DK96913234T DK0830141T3 DK 0830141 T3 DK0830141 T3 DK 0830141T3 DK 96913234 T DK96913234 T DK 96913234T DK 96913234 T DK96913234 T DK 96913234T DK 0830141 T3 DK0830141 T3 DK 0830141T3
- Authority
- DK
- Denmark
- Prior art keywords
- virus
- strains
- inactivated
- neuraminidase
- hemagglutinin
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 11
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108010006232 Neuraminidase Proteins 0.000 abstract 3
- 102000005348 Neuraminidase Human genes 0.000 abstract 3
- 239000000185 hemagglutinin Substances 0.000 abstract 3
- 101710091045 Envelope protein Proteins 0.000 abstract 2
- 101710154606 Hemagglutinin Proteins 0.000 abstract 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 2
- 101710176177 Protein A56 Proteins 0.000 abstract 2
- 101710188315 Protein X Proteins 0.000 abstract 2
- 102100021696 Syncytin-1 Human genes 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 229960003971 influenza vaccine Drugs 0.000 abstract 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 abstract 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 abstract 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 241000712079 Measles morbillivirus Species 0.000 abstract 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 abstract 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/430,971 US5976552A (en) | 1995-04-28 | 1995-04-28 | Virus vaccines |
| PCT/US1996/005904 WO1996033738A1 (fr) | 1995-04-28 | 1996-04-26 | Vaccins antiviraux ameliores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0830141T3 true DK0830141T3 (da) | 2003-10-20 |
Family
ID=23709884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96913234T DK0830141T3 (da) | 1995-04-28 | 1996-04-26 | Forbedrede virusvacciner |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5976552A (fr) |
| EP (1) | EP0830141B1 (fr) |
| CN (1) | CN1141977C (fr) |
| AT (1) | ATE243530T1 (fr) |
| AU (1) | AU696690B2 (fr) |
| CA (1) | CA2222283C (fr) |
| DE (1) | DE69628834T2 (fr) |
| DK (1) | DK0830141T3 (fr) |
| ES (1) | ES2201184T3 (fr) |
| PT (1) | PT830141E (fr) |
| WO (1) | WO1996033738A1 (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485729B1 (en) * | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
| ES2267127T3 (es) * | 1996-10-31 | 2007-03-01 | Slk Foundation | Composicion saborizante, su produccion y su utilizacion. |
| WO1998046262A1 (fr) * | 1997-04-16 | 1998-10-22 | Connaught Laboratories, Inc. | Compositions anti-grippe completees par la neuraminidase |
| NZ512980A (en) * | 1998-12-17 | 2003-07-25 | Aventis Pasteur | Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation |
| AT407958B (de) * | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
| NZ517903A (en) * | 1999-09-24 | 2003-10-31 | Smithkline Beecham Biolog S | One dose intranasal influenza virus vaccine with split influenza viral antigens |
| US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
| US7611700B2 (en) * | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
| US20040141947A1 (en) | 2002-10-16 | 2004-07-22 | Hunter Samuel F. | Method for treatment of demyelinating central nervous system disease |
| US20060110740A1 (en) * | 2003-01-20 | 2006-05-25 | Julia Hurwitz | Use of sendai virus as a human parainfluenza vaccine |
| TWI295995B (en) * | 2003-08-19 | 2008-04-21 | Academia Sinica | Protein isolation |
| JP2008527009A (ja) | 2005-01-19 | 2008-07-24 | バクシネート コーポレーション | 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用 |
| GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| KR20080052512A (ko) * | 2005-05-23 | 2008-06-11 | 박신, 인크. | 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산 |
| WO2007057763A2 (fr) * | 2005-11-18 | 2007-05-24 | Pulmonox Technologies Corporation | Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin |
| US9333249B2 (en) | 2006-02-09 | 2016-05-10 | Educational Foundation Jichi Medical University | Recombinant baculovirus vaccine |
| TWI477602B (zh) | 2006-02-09 | 2015-03-21 | Educational Foundation Jichi Medical Univ | Novel viral vector |
| EP2476432B1 (fr) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions incluant de l'hémagglutinine, procédés pour leur fabrication et leurs méthodes d'utilisation |
| US20090060889A1 (en) * | 2007-03-12 | 2009-03-05 | Von Hofe Eric | Ii-RNAi involved Ii suppression in cancer immunotherapy |
| CN101307310B (zh) * | 2007-05-15 | 2012-08-08 | 康泰生医科技股份有限公司 | 具有提高产率及免疫原性的重组蛋白质表达系统 |
| EP2014279A1 (fr) * | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomes contenant de l'hémagglutinine dérivée du virus de la grippe produit par les lignées cellulaires; les compositions, les méthodes de production, l'emploi des virosomes |
| SG190562A1 (en) | 2008-04-18 | 2013-06-28 | Vaxinnate Corp | Deletion mutants of flagellin and methods of use |
| WO2010144797A2 (fr) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations |
| MX2012007916A (es) * | 2010-01-06 | 2012-11-06 | Vaxinnate Corp | Metodos y composiciones para proporcionar inmunidad protectora en los adultos mayores. |
| EP2579892A2 (fr) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable |
| EP2650362A4 (fr) * | 2010-11-02 | 2014-10-01 | López Hector Manuel Zepeda | Nouveaux vaccins contre le virus de la grippe pandémique a/h1n1 |
| KR20200008014A (ko) | 2011-03-21 | 2020-01-22 | 알티뮨 인크. | 급속 및 지속적 면역학적제제-치료제 |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| AU2017207744A1 (en) | 2016-01-11 | 2018-07-26 | Verndari, Inc. | Microneedle compositions and methods of using same |
| CN105854009A (zh) * | 2016-05-03 | 2016-08-17 | 重庆三杰众鑫生物工程有限公司 | 应用番鸭肝炎病毒制备灭活疫苗的制备方法 |
| MX2023012554A (es) | 2018-12-12 | 2023-11-08 | Cambridge Tech Llc | Vacuna universal contra la gripe. |
| AU2022379948A1 (en) | 2021-11-05 | 2024-06-20 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
| CA3237139A1 (fr) | 2021-11-05 | 2023-05-11 | Sanofi | Vaccins contre la grippe multivalents hybrides comprenant de l'hemagglutinine et de la neuraminidase et leurs procedes d'utilisation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2667245B1 (fr) * | 1990-10-01 | 1992-11-06 | Rhone Merieux | Association vaccinale contre les pathogenes infectieux. |
| CA2139756A1 (fr) * | 1992-07-08 | 1994-01-20 | Eric M. Bonnem | Utilisation du gm-csf comme adjuvant vaccinal |
-
1995
- 1995-04-28 US US08/430,971 patent/US5976552A/en not_active Expired - Lifetime
-
1996
- 1996-04-26 CN CNB961950706A patent/CN1141977C/zh not_active Expired - Fee Related
- 1996-04-26 PT PT96913234T patent/PT830141E/pt unknown
- 1996-04-26 WO PCT/US1996/005904 patent/WO1996033738A1/fr not_active Ceased
- 1996-04-26 DK DK96913234T patent/DK0830141T3/da active
- 1996-04-26 CA CA2222283A patent/CA2222283C/fr not_active Expired - Fee Related
- 1996-04-26 AT AT96913234T patent/ATE243530T1/de active
- 1996-04-26 AU AU56312/96A patent/AU696690B2/en not_active Revoked
- 1996-04-26 DE DE69628834T patent/DE69628834T2/de not_active Expired - Lifetime
- 1996-04-26 EP EP96913234A patent/EP0830141B1/fr not_active Expired - Lifetime
- 1996-04-26 ES ES96913234T patent/ES2201184T3/es not_active Expired - Lifetime
-
1999
- 1999-01-22 US US09/235,901 patent/US20020071848A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1141977C (zh) | 2004-03-17 |
| CN1189103A (zh) | 1998-07-29 |
| CA2222283C (fr) | 2015-02-03 |
| PT830141E (pt) | 2003-11-28 |
| EP0830141B1 (fr) | 2003-06-25 |
| DE69628834D1 (de) | 2003-07-31 |
| EP0830141A1 (fr) | 1998-03-25 |
| HK1013595A1 (en) | 1999-09-03 |
| AU696690B2 (en) | 1998-09-17 |
| ATE243530T1 (de) | 2003-07-15 |
| US20020071848A1 (en) | 2002-06-13 |
| AU5631296A (en) | 1996-11-18 |
| US5976552A (en) | 1999-11-02 |
| WO1996033738A1 (fr) | 1996-10-31 |
| ES2201184T3 (es) | 2004-03-16 |
| CA2222283A1 (fr) | 1996-10-31 |
| DE69628834T2 (de) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0830141T3 (da) | Forbedrede virusvacciner | |
| Hashigucci et al. | Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin | |
| EP0705109B2 (fr) | Adjuvants pour vaccins contre le virus respiratoire syncytial | |
| AU2684792A (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
| FI905184A0 (fi) | Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3. | |
| DK0584348T3 (da) | Genetisk vaccine mod immundefektvirusser | |
| RU2000116260A (ru) | Вакцины с адъювантом ltb | |
| RU94042386A (ru) | Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита | |
| EA200000528A1 (ru) | Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией | |
| MX9802285A (es) | Vacunas y glicoproteinas de virus de parainfluenza. | |
| ES2127294T3 (es) | Vacunas del virus de la inmunodeficiencia anti-felino (fiv). | |
| DE3689622D1 (de) | Impfstoffe gegen menschliche respiratorische viren. | |
| Downie | Neuraminidase-and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B/Eng/13/65 virus vaccines | |
| AU3887695A (en) | Interleukin-12 as an adjuvant for paramyxoviridae vaccines | |
| EP0270295A3 (fr) | Vaccin conjugué | |
| IE32140B1 (en) | Vaccines | |
| DE69720024D1 (de) | Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten | |
| Liashenko et al. | Measles IgA in the nasal washings of adult volunteers and children immunized intranasally with measles vaccine L-16 | |
| BR9909076A (pt) | Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b | |
| WO2001083528A3 (fr) | Immunisation au moyen d'acide nucleique | |
| PT100460A (pt) | Partiiculas derivadas de virus de herpes e vacinas que as contem | |
| Kikuta et al. | Enhancement of DTH response by cholera toxin B subunit inoculated intranasally together with influenza HA vaccine | |
| GB1413401A (en) | Influenza vaccine | |
| Trudel et al. | Efficient intranasal vaccination of mice against human respiratory syncytial virus with an experimental iscoms subunit vaccine | |
| Reddy et al. | Efficacy of a combined live attenuated canine distemper and inactivated rabies vaccine in dogs |